

# Curriculum Vitae

Nils Ove Hoem, M.Sc.(Pharm), Ph. D.

## PROFESSIONAL BACKGROUND

---

Academic Appointments	1985-1989	Research Assistant, Department of Pharmacology, School of Pharmacy, University of Oslo.
	1989-1990	Assistant Professor, Department of Pharmacology, School of Pharmacy, University of Oslo.
	1990-1998	Associate Professor, Department of Pharmacology, School of Pharmacy, University of Oslo.
	2000-2004	Associate Professor, Department of Pharmacology, School of Pharmacy, University of Oslo
	2001-2014	Associated member of Laboratory of Applied Pharmacokinetics, USC, Los Angeles
Non-Academic appointments	1979-1980	Teacher (Ellingsoy Junior High School)
	1984 - 2004	Several shorter periods (1-4 weeks) as community Pharmacist in Norway
	1992-1996	Project manager: Development and implementation of a Post Graduate one-year continuing education program for Pharmacists.
	1999	Senior Regulatory Advisor, Smerud Medical Research Group, Oslo, Norway.
	2003	Senior Scientific Consultant, Smerud Medical Research Group, Oslo, Norway.
	2003-2004	Running own consultancy business. Hoem Pharma Consult in Oslo Norway. Consulting in Pharmacokinetics and in more general aspects of early drug development.
	2004-2007	Director PK/PD (Europe) MDS Pharma Services, Hamburg, Germany and Belfast Northern-Ireland
	2007-2007	Director R&D Pronova Biocare AS, Lysaker, Norway
2008-2010	Vice President Research and Development Aker BioMarine, Norway	
2011-present	Chief Scientist Aker BioMarine, Norway	

## LICENSURE

---

1983 - present Certified to Dispense Drugs in Norway.

## HONOURS AND AWARDS

---

1993-1997	Appointed Member of the Drug Approval Board, Norwegian Medicinal Authority, by Norwegian Minister of Health and Social Services.
1993	Member of Scientific Committee, European Workshop on Clinical Pharmacy, Oslo, June 1993.
1997 -1998	Member of organizing Committee 3 <sup>rd</sup> International Congress for Lifelong Learning in Pharmacy, Hillerod, Denmark, June 1998.
1996	Member of jury (2 <sup>nd</sup> opponent) evaluation of Doctoral Thesis: Quy, N Diep; "Pivalic acid containing antibiotics induced carnitine deficiency", University of Oslo.
1999	Member of jury (3 <sup>rd</sup> opponent) evaluation of Doctoral Thesis: Anders Aasberg; "Effects of Cyclosporine A on microvascular function and endothelin-1 in renal transplant recipients.", University of Oslo.
2000	Member of jury (3 <sup>rd</sup> opponent) evaluation of Doctoral Thesis: Ole Andreas Loechen Oekstad; "Sequence analysis of Bacillus cereus genome fragments: A comparative genome analysis." University of Oslo.
2000	Doctoral Thesis Advisory Committee; Siri Wang, "Aspects of ascorbic acid kinetics. In vivo and in vitro studies with focus on methodology.", University of Oslo.
2000-2001	Sabbatical, September 2000-September 2001. Sponsor University of Oslo and Norwegian Research Council. Visiting Scientist with professor Roger Jelliffe at the Laboratory of Applied Pharmacokinetics, Keck School of Medicine, University of Southern California, Los Angeles.
2009	External member of jury evaluation of Doctoral Thesis: "Optimisation de l'utilisation des techniques de modélisation dans le processus de développement d'un médicament: de l'étape pré-clinique à clinique." University of Montreal, February 2009.
2011	External expert during dissertation of Doctoral Thesis: "Development and Evaluation of Nonparametric Mixed Effects Models"Uppsala University, March 2011.

## EDUCATION

---

Undergraduate Studies	1977 - 1982	School of Pharmacy, University of Oslo, Norway
Graduate studies	1982-1983	Department of Pharmacology, School of Pharmacy, University of Oslo and Nycomed A/S, Oslo, Norway.

Post graduate studies	1983	MS (pharm): Thesis; "Measurement of arterial blood pressure and plasma level of prekallikrein, high molecular weight kininogen and plasminogen activator in rats after vascular administration of X-ray contrast media (Biligradin and Omnipaque) N Hoem, S Ekelund."
Ph.D.- studies	1983-1990	Department of Pharmacology, School of Pharmacy, University of Oslo
	1985	PBF 455 Clinical Pharmacology: Doctorate level course (4 credits).
	1984	PBF 453 Toxicology: Doctorate level course (5 credits)
Doctorate	1992	Public Defense of Doctor Philosophiae. Thesis: "Studies on levels and interactions of contact activation factors in plasma: A basis for the elucidation of their function in anaphylactoid reactions to dextran and to radiographic contrast media"
Participation in workshops and shorter courses	1992	Qualifying course for teaching responsibilities in higher education in Norway part 1
	1993	Qualifying course for teaching responsibilities in higher education in Norway part 2
	1993	Bayesian Individualization of Drug Dosage Regimens, Nonparametric EM population Pharmacokinetic EM Modeling, Modeling Drug Diffusion into Endocardial Vegetations and Bacterial Killing Curves, Satellite Workshop during 3 <sup>rd</sup> World Congress on TDM, Philadelphia.
	1996	SAAM II Kinetic Modeling Workshop, City University, London, UK
	1998	Intermediate and Advanced population modeling, and application to model based, goal oriented individualized drug therapy, LAPK, USC, Los Angeles
	2000	Workshop on Conducting Successful Clinical Trials, University of California, San Francisco.
	2000	9 <sup>th</sup> Workshop on Advanced Methods of PK/PD Systems Analysis, University of Southern California, Biomedical Simulations Resource, Marina Del Rey, CA, USA,
	2005	SMi's 8th Annual Conference Generics, Supergenerics & Patent Strategies, London; UK.

SPECIFIC TEACHING RESPONSIBILITIES

---

Undergraduate Level	1985 – 1993	Instructor in Experimental pharmacology , part of 5 credit (full year=20 credits) subject PBF 250 Pharmacodynamics, and PBF 150 Physiology with Anatomy (4 credits).
	1985-1993	Course Coordinator PBF 250 Pharmacodynamics experimental course during 6 terms, School of Pharmacy, University of Oslo.
	1993-2003	Lectures in PBF 251 Basic Pharmacology (5 credits) for 3rd year Pharmacy students, University of Oslo.
	1993	Master plan and description of main objectives for a new 4 credit course (PBF 252) in Clinical Pharmacology at The School of Pharmacy, University of Oslo
	1993-2002	Lectures in PBF151 Physiology (3 credits) for 2 <sup>nd</sup> year Pharmacy students, University of Oslo
	2000-2001	Course coordinator PBF 151 Physiology, School of Pharmacy, University of Oslo.
Graduate Level	1990 and 1992	Course coordinator for PBF 355Clinical Pharmacokinetics, School of Pharmacy, University of Oslo.
Post Graduate Level	1996 – 1998	Course Coordinator PBF 353 Advanced Pharmacology
	1992-1997	Lectures in PVA330: “Advanced Topics in Pharmaceutical Sciences” (2/3 of 3 credits). Department of continuing and post graduate education, School of Pharmacy, University of Oslo
	1992-1995	Course coordinator one-year course: Advanced Diploma in Community Pharmacy.
	1994, 1996	Course coordinator PBF 455 Clinical Pharmacokinetics, Department of postgraduate and continuing education, School of Pharmacy, University of Oslo. In 1996 this course was classified as a National Research course
	2001	PBF 455 Clinical Pharmacokinetics. Organized as one-year distance education Course using the VETTUS tool. Sole lecturer and Instructor at the same course (4 credits), University of Oslo.
Supervisor	1984-2005	Supervisor for more than 15 individual one-year long master’s student research projects in the field of Contact Activation, Coagulation and Fibrinolytic Cascade System biology and pathophysiology, Department of Pharmacology, School of Pharmacy, Univ of Oslo

Ph. D project Supervisor	1994-1997	Supervisor of 2 student diploma projects, part of a one year long, advanced continuing education program for community Pharmacists, University of Oslo. Ph.D student Siv Fossum.
	1992-1997	
	2000	Ph.D student Siri Wang.
	2000 - 2005	Ph.D. Student: Kristin C. Carlsson, School of Pharmacy, University of Oslo.
Co-supervisor	1990 -present	Co-supervisor for more than 30 one year long master's student research projects in Pharmacology, University of Oslo.
	1996	Co-Supervisor one year long master's student research project in Pharmacology at Thrombosis Research Center, Temple University, Philadelphia.
	1998-1999	Co-supervisor for 2 one year long master's student research projects in Pharmacology, University of Tromso.
	2016-2019	Co-supervisor for 2 PhD students at IMAS, University of Tasmania
Continuing education Courses and Continuing education Workshops	1996 - 1997	Internet for Pharmacists, One day Workshop, Pharmakon, Hillerod, Denmark
		Seven, one day hands on workshops on emerging net-based Information Technologies in the Pharmaceutical Sciences and Pharmaceutical Practice, Bodo, Tromso, Drammen, Forde, Aalesund, Brevik.
	1998	
	1999	Internet in the Pharmaceutical and Medical Fields. One day Hands on Workshop, Pharmakon, Hillerod, Denmark
		Net based Information technologies in the Health Professions, Oslo
	1999-2000	Co-developer of VETTUS a Web based tool for Continuing and Post-Graduate Education, University of Oslo
	1998-2006	Several workshops in Population PK together with Professor Roger Jelliffe at LAPK, University of Southern California. Workshops held in the US, Spain, Italy, France and Switzerland.

## SPECIFIC ACADEMIC ADMINISTRATIVE RESPONSIBILITIES

---

1981-1982	Delegate to The students Parliament, University of Oslo
1986, 1987	Member of Senate, School of Pharmacy, representing Ph. D students and research assistants.
1986-1994	Member of Technical Affair and Equipment Committee, School of Pharmacy, University of Oslo.
1987-1997	Member of Computers and Information Technology Committee, School of Pharmacy, University of Oslo.
1989-1994	Member of Clinical Pharmacy Committee of the Norwegian Pharmaceutical Society, representing University of Oslo. The Committee did during this period develop and implement a three-year specialization program in Clinical/Hospital Pharmacy.
1989-1995	Member of Board of the Continuing Education of Pharmacists Committee.
1990-1991	Vice-President of Board of the Continuing Education of Pharmacists Committee.
1991-1992	Appointed member of committee evaluating the establishment of a one year post-graduate educational specialization program for Community Pharmacists in Norway.
1991	Member of Working group for establishing an Independent Department of Continuing and Postgraduate Education at The School of Pharmacy, University of Oslo.
1991-1993	Deputy member of Senate, School of Pharmacy, representing Scientific Faculty.
1991-1994	Member; Reference group for establishing a School of Pharmacy, University of Tromsøe
1997-1998	Member; Curriculum evaluation committee, School of Pharmacy, University of Oslo.
1998	Member, working group for evaluation of present, and propose new infrastructure of student oriented IT-technologies, Faculty of Mathematics and Natural Sciences, University of Oslo.
1999 - 2000	Head of Department, Department of Pharmacology, School of Pharmacy, University of Oslo.
2000-2002	Member; Curriculum revision working group, School of Pharmacy, University of Oslo.
1993-2002	Member of Senate, School of Pharmacy.

## PROFESSIONAL MEMBERSHIPS

---

1984 - 2004	Norwegian Society for Pharmacology and Toxicology
1984 - 2000	Norwegian Association of Pharmacists.
1993 -1999	European Society of Clinical Pharmacy
1993 -1998	New York Academy of Sciences
1990 -2004	Norwegian Association of Research Scientists
1999	Norwegian Society for Regulatory Affairs Associates
1999-2001	Norwegian Polytechnic Society
2000 - 2003	International Association of Therapeutic Drug Monitoring and Clinical Toxicology
2001 - 2003 2012 - present	American Society for Clinical Pharmacology and Therapeutics
2008 - 2011	Member of EUFEPS CIRR committee
2019-	American Society for the Advancement of Science

---

## CONSULTANT

1992	Scientific Reviewer, Pharmacology and Toxicology, Munksgaard, Copenhagen.
1997-1999	Scientific consultant: The KLOK project: Developing a computerized system for drug interaction warning, as integral part of General Practitioners Computerized Patient Record and Administration System. CPC Scandinavia, Subsidiary of MSD, Drammen, Norway
1999	Scientific project reviewer, NATO Advanced Study proposal.
2000	Consultant, Pharmacokinetic trial design and analysis, Drug development, Photocure ASA, Oslo Norway.
	Consultant, General Pharmacology and Pharmacokinetics, Drug development Project, Ernst & Young Consultants, Oslo Norway
2000-2003	Scientific Consultant, Smerud Medical Research Group, Oslo Norway.
2003-2004	Consultant, Pharmacokinetic trial design and analysis, Drug Development, Conjuchem Inc., Montreal, Canada,

2001-2007	Consultant, Pharmacokinetic trial design and analysis, Drug development, Alexion Pharmaceuticals Inc., Cheshire, CT, USA.
2008-2010	Member of Pain Management Advisory Board, Egalet APS, Denmark

#### RESEARCH SUPPORT

---

1984 - 1989	Norwegian Pharmaceutical Society, Research support Fund, \$ 5000
1991-1994	Norwegian Association of Pharmacy Proprietors, Pharmaceutical Research Fund, \$160000,-
1991-1995	Norwegian Governmental Medicinal Products Whole-Sale organization: Pharmacological Research Fund, \$12000
1999-2000	Norwegian Research Council; New Equipment support: LC- MS MS; \$ 175 000.
2000-2001	Norwegian Research Council: Sabbatical Support, \$ 32000.

#### LANGUAGES

---

Norwegian, English; fluently

German: Near fluent.

Swedish and Danish; uninhibited oral and written understanding but restricted ability in writing and speaking.



## PUBLICATIONS

---

Articles in peer-reviewed publications.

1. HOEM, N.-O and BRISEID, K. Reduced cofactor function of human high molecular weight kininogen induced by rat plasma kallikrein. *Acta pharmacol. et toxicol.* 57, 47-52, 1985.
2. HOEM, N.-O. and BRISEID, K. Activation of factor XII in acetone-treated human plasma: Significance of the functional state of plasma kallikrein for the extent of activation. *Acta pharmacol. et toxicol.* 59, 144-150, 1986.
3. HOEM, N.-O., BRISEID, G., EKELUND, S. and SALVESEN, S. Effects of intravenous radiographic contrast media on the blood pressure and on factors of the contact activation system in the rat. *Acta pharmacol. et toxicol.* 59, 189-194, 1986.
4. HOEM, N.-O. and BRISEID, G. Acetylcysteine in rats: Inhibition of activation of prekallikrein and factor XII - Protection against dextran-induced blood pressure fall. *Pharmacology & Toxicology*, 60, 140-144, 1987.
5. JOHANSEN, H.T., HOEM, N.-O., VEGGELAND, T. and BRISEID, K. Assay kallikrein inhibitors and levels of acetone-activated kallikrein in plasma specimens from reactors to dextran or to contrast media. *Int. J. Tiss. Reac.* 8, 185-192, 19
6. HOEM, N.-O., JOHANSEN, H. T., JOHANNESSEN, S. and BRISEID, K. Rock immunoassay of high and low molecular weight kininogens in human plasma. *Advances in Experimental Medicine and Biology*, 247A, Kinins V. K. Abe, H.t S. Fujii (Eds.), New York-London: Plenum Press, 1989, pp.337-343.
7. HOEM N.-O., JOHANNESSEN, S. and BRISEID, K. Assay of factor XII in human plasma using prekallikrein or the chromogenic peptide S-2222 as substrates. Significance of the functional state of plasma kallikrein. *Thromb. Res.* 54, 197- 1989.
8. BRISEID, K., HOEM, N.-O., JOHANNESSEN, S. and MARTINSEN, K. Functional correlation between kallikrein and factor XII activated in human plasma and the. *Thromb. Res.* 57, 945- 956, 1990

9. STORMORKEN, H., BRISEID, K., HELLMUM, B., HOEM, N.-O., JOHANSEN, H. T. and LY, B. A new case of total kininogen deficiency. *Thromb. Res.* 60, 457A67, 1990.
10. BRISEID, K., HOEM, N.-O., JOHANNESSEN, S. and FOSSUM S. Contact activation factors in plasma from pregnantwomen. Increased level of an association between factorXII and kallikrein. *Thromb. Res.* 61, 123-133, 1991.
11. HOEM, N.-O., JOHANNESSEN, S., HAUGE, G., RUD, A. C., SANDEM, S. and BRISEID, K. Contact activation factors in plasma from women using oral contraceptives - Increased levels of factor XII, kinin-free high molecular weight kininogen and acetone-activated kallikrein. *Thromb. Res.* 64, 427-434, 1991.
12. HOEM, N.-O., JOHANNESSEN, S. and BRISEID, K. Formation of an association between factor XII and kallikrein in human plasma- Significance of storage of plasma and the functional State of plasma kallikrein. *Thromb. Res.* 66, 421-434, 1992.
13. HOEM, N.-O. Studies on levels and interactions of contact activation factors in plasma. A basis for the elucidation of their function in anaphylactoid reactions to dextran and to radiographic contrast media. *Thesis for the degree of Dr. Philos.*, School of Pharmacy, University of Oslo, 1992, ISBN 82-91094-01-2.
14. FOSSUM, S., HOEM, N.-O., JOHANNESSEN, S., KORPBERGET, M., NYLUND, E SAND EM, S. and BRISEID, K. Contact factors in plasma from women on oral contraception - Significance of factor XI for the measured activity of factor XII. *Thromb. Res.* 74, 477-485, 1994.
15. BRISEID, K., HOEM, N.-O., JOHANNESSEN, S. and HAUG, K. Amidolytic assay of factor XI in human plasma - Significance of kallikrein for the activity measured. *Thromb. Res.* 78, 239-250, 1995.
16. BRISEID, K., HOEM, N.-O., JOHANNESSEN, S., VANGEN, M., WESTGAARD, T.: Significance of IgG for the activity of factor XII measured in human plasma. *Scand Clin. Lab. Invest.* 56, 725-734, 1996.

- 17 SATAS, S, JOHANNESSEN, S.I, HOEM, N.O, HAALAND, K., SORENSEN, D.R., THORESEN, M. Lidocaine pharmacokinetics and toxicity in newborn pigs. *Anesth. Analg.* 85,306-312,1997
- 18 BRISEID K, HOEM N.O., JOHANNESSEN S. Part of prekallikrein removed from human plasma together with IgG - immunoblot experiments and functional tests. *Scand. J. Clin. Lab. Invest.* 59, 1-9, 1999.
- 19 FOSSUM, S., HOEM, N.O., GJONNAESS., H., BRISEID, K. Contact activation factors in plasma from women on estrogen replacement therapy after ovariectomy. *Thromb Res*, 93, 161-70, 1999.
- 20 SATAS, S., HOEM, N., MELBY, K., PORTER, H., WHITELAW, A., THORESEN, Influence of mild hypothermia after hypoxia-ischemia on the pharmacokinetics of gentamicin in newborn pigs. *Biology of the neonate*, 77, 50-57, 2000.
21. SATAS, S., HOEM, N., MELBY, K., PORTER, H., WHITELAW, A., THORESEN, Influence of mild hypothermia after hypoxia-ischemia on the pharmacokinetics of gentamicin in newborn pigs. *Biology of the neonate*, 77, 50-57, 2000.
- 22 WANG, S., BERGE, G.E., HOEM, N.O., SUND, R.B. Ascorbic Pharmacokinetics in dogs after oral administration of two different forms of ascorbic acid. *Res Vet Sci.* 2001 Aug;71(1):27-32.
- 23 CARLSSON, KC, HOEM, NO, MOBERG, ER, MATHIESEN, LC . Analgesic effect of dextromethorphan in neuropathic pain. *Acta Anaesthesiol Scand.* 2004 Mar; 48(3):328-36.
- 24 CARLSSON, KC, HOEM, NO, GLAUSER,T, VINKS, AA. Development of a Population Pharmacokinetic Model for Carbamazepine Based on Sparse Therapeutic Monitoring Data from Pediatric Patients with Epilepsy *Clin Ther* 2005;27:618-26 .
- 25 BERINGER, P, NGUYEN, M, HOEM,N, LOUIE, S, GILL, M, GUREVITCH, M, BERINGER, AW: Absolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral Feedings *Antimicrob. Agents Chemother.* 2005 49: 3676-3681.

26. BERINGER, P, HUYNH KM, KRIENGKAUYKIAT J, BI L, HOEM N, LOUIE S, HAN E, NGUYEN T, HSU D, RAO PA, SHAPIRO B, GILL M. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. *Antimicrob Agents Chemother.* 2005 Dec; 49(12):5013-7.
27. CARLSSON, K.C., van de SCHOOTBRUGGE, HANSEN, H., MOBERG, E.R., HOEM, N.O. A Population Pharmacokinetic Model of Gabapentin in Neuropathic Pain Patients. *Ther Drug Monit.* 2009 Feb; 31(1):86-94.
28. WINTHER, B. , HOEM N., BERGE K., REUBSAET L.: Elucidation of phospholipid composition in krill oil extracted from *Euphausia Superba*. *Lipids.* 2011 Jan; 46(1):25-36.
29. KIRKHUS B, LAMGLAIT A, EILERTSEN KE, FALCH E, HAIDER T, VIK H, HOEM N, HAGVE TA, BASU S, OLSEN E, SELJEFLOT I, NYBERG L, ELIND E, ULVEN S. Effects of similar intakes of marine n-3 fatty acids from enriched food products and fish oil on cardiovascular risk markers in healthy humans. *Journal of Nutrition*, 2012; Vol 107 , 9, pp 1339-1349
30. BURRI L, HOEM N, BANNI S, BERGE K: Review. Marine omega-3 phospholipids: metabolism and biological activities. *Int J Mol Sci* 2012, 13:15401-15419.
31. BERGE K., PISCITELLI F, HOEM N, SILVESTRI C, MEYER I, SEBASTIANO BANNI S, DI MARZO V: Chronic treatment with krill oil powder reduces plasma triglyceride and anandamide levels in mildly obese men. *Lipids Health Dis.* 2013 May 27;12:78
32. BERGE K, MUSA-VELOSO K, HARWOOD M, HOEM N, BURRI L: Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. *Nutr Res.* 2014 Feb; 34(2):126-33.
33. HOEM N. Challenging the claim that intake of krill oil is associated with increased metabolic risk in overweight men. *Am J Clin Nutr.* 2016 Jun;103(6):1557-8
34. BURRI, L, HOEM, N., MONAKHOVA, Y B., DIEHL B W K. FINGERPRINTING Krill Oil by 31P, 1H and 13C NMR Spectroscopies. *J Am Oil Chem Soc* (2016) 93:1037–1049

35. HOEM N. Challenging the claim that intake of krill oil is associated with increased metabolic risk in overweight men. *Am J Clin Nutr.* 2016 Jun;103(6):1557-8
36. ERICSON JA, HELLESSEY N, KAWAGUCHI S, NICOL S, NICHOLS PD, HOEM N, VIRTUE P. Seasonal and interannual variations in the fatty acid composition of adult *Euphausia superba* Dana, 1850 (Euphausiacea) samples derived from the Scotia Sea krill fishery. *Journal of Crustacean Biology*, Volume 38, Issue 6, 22 November 2018, Pages 656–661,
37. HELLESSEY N, ERICSON JA, KAWAGUCHI S, NICOL S, NICHOLS PD, HOEM N, VIRTUE P. Seasonal and interannual variation in the lipid content and composition of *Euphausia superba* Dana, 1850 (Euphausiacea) samples derived from the Scotia Sea fishery. *Journal of Crustacean Biology*, Volume 38, Issue 6, 22 November 2018, Pages 673–681,
38. ERICSON JA, HELLESSEY N, KAWAGUCHI S, NICOL S, NICHOLS PD, HOEM N, VIRTUE P. Adult Antarctic krill proves resilient in a simulated high CO<sub>2</sub> ocean. *Commun Biol.* 2018 Nov 13;1:190.
39. ERICSON J. A., HELLESSEY N, NICHOLS P. D., NICOL S., KAWAGUCHI S., HOEM N, VIRTUE P.:  
New insights into the seasonal diet of Antarctic krill using triacylglycerol and phospholipid fatty acids. *Polar Biology*, November 2019 Volume 42, Issue 11, pp 1985-1996,
40. HELLESSEY N, ERICSON JA, KAWAGUCHI S, NICOL S, NICHOLS PD, HOEM N, VIRTUE P. Antarctic Krill (*Euphausia superba* Dana 1850) Lipid and Fatty acid Content 85 Variability is associated to Satellite Derived Chlorophyll a and Sea Surface Temperatures. *Under review at Nature Scientific Reports*
41. HELLESSEY N, ERICSON JA, KAWAGUCHI S, NICOL S, NICHOLS PD, HOEM N, VIRTUE P. Regional variability of Antarctic krill (*Euphausia superba*) diet as determined using lipid, fatty 77 acid and sterol composition. *Polar Biology* (under review)

Presentations and Posters at meetings, conferences and congresses.

1. HOEM, N. O., BRISEID, G., EKELUND, S., SALVESEN, S. Effects of intravenous radiopgraphic contrast media on the blood pressure and on factors of the contact phase system in the rat. *Presentation, Winter meeting, Norwegian Society for Pharmacology and Toxicology, Beito, Norway, January 23-26 1986.*
2. HOEM, N.-O., BRISEID, G. Acetylcystein i rotte: Inhibisjon av aktiveringne prekallikrein og faktor XII - beskyttelse mot dekstran-indusert blodtrykksfal *Presentation, Farmasidagene, Blindern, Norway, October 27. 1986.*
3. HOEM, N.-O., JOHANSEN, H. T., JOHANNESSEN, S., BRISEID, K. Rock immunoassay of high and low molecular weight kininogens in human plasma. *Presentation, Kinin V. International Congress on Kinin, November 29 - December 3, Tokyo, Japan.*
4. JOHANSEN, H. T., ENG H, K. M., HOEM, N.-O. Hoymolekylaert kininogen. Effekten av plasma kallikrein paa kofaktorfunksjonen. *Presentation, Farmasidagene, Blindern, Norway October 24. 1988.*
5. BRISEID, K. and HOEM, N.-O. Assay of factor XII in human plasma – Significance of the functional state of plasma kallikrein. *Poster, Gordon Research Confrence on Kallikrein and Kinins, Oxnard, California, 22.- 17.January, 1989.*
6. STORMORKEN, H., BRISEID, K., HELLUM, B., HOEM, N.O., JOHANSEN, and LY, B. A new case of kininogen deficiency. *Presentation during XII. Isth, Japan 1989.*
7. HOEM, N.-O., EIDE, G., HORVEI, K., KEUSE-JENSEN, A., I. WOLD. Postgraduate education in hospital pharmacy in Norway. *Presentation, Lifelong learning in pharmaceutical sciences and services, 1st international conference. Hillered, Denmark, 1990.*
8. BRISEID, K., HOEM, N.-O. and S. JOHANNESSEN. Factor XII, kallikrein and high molecular weight kininogen are present in association in human plasma acetone-activated in the presence of benzamidine. *Poster, Gordon Research Confrence on Kallikrein and Kinins, Ventura, California, 18 - 22.ftbruar 1991.*

9. HOEM, N. -O., JOHANNESSEN, S., HAUGE, G., RUD, A. C., SANDEM, S., BRISEID, K. Contact activation factors in plasma from women using oral contraceptives. *Poster, Kinin V, International Congress on Kinin, September 8 -24, 1991, Munchen, Germany.*
10. ERIKSEN, I. L., FINSTAD, E., HOEM, N.-O. Advanced diploma in community pharmacy. A post-graduate program involving both traditional and long-distance educational methods. *Poster PIP International Congress, Tokyo, Japan, September 1993*
11. BRISEID K., HOEM, N.-O., FOSSUM, S., JOHANNESSEN, S. Increased level factor XII, prekarnkrein and plasminogen proactivators in plasma from women on a low estrogen dose oral contraceptive. Significance of factor XI for activity levels of factor XIIa and kallikrein. *Poster, Kinin VI 93 Brazil, International Congress, Guarujá, Brazil, October 27-22, 1993.*
12. HOEM, N.-O. Diplomstudiet i apotekfarmasi. Et ettaarig og universitetsstudium i apotekfarmasi. Status og erfaringer etter foerste studieaar. *Presentation. 16th. Nordic Congress on Pharmacy, Reykjavik 22.-Iceland. June 1994.*
13. HOEM, N.-O, HUSEMOEN, R. Advanced diploma in community pharmacy Program involving both traditional and long-distance educational methods. *Presentation, poster and practical demonstration. The Second International Conference on Lifelong Learning in Pharmacy, Madison, WI, U.S.A., August 22-26, 1994.*
14. BRISEID, K., HOEM, N.-O., S. JOHANNESSEN, HAUG, K. Amidolytic assay of factor XI in human plasma - Significance of kallikrein for the activity measured. *Poster, Gordon Research Conference on Kallikrein and Kinins, Ventura, California, February 1995.*
15. HOEM, N. O. Internetbasert fjernundervisning. (Internet as a tool for distance education). *Invited presentation and demonstration, Headquarters, Apotekarsocieteten, Stockholm, 1994.*
16. SATAS, S., JOHANNESSEN, S., HOEM, N. O., HAALAND, K., SORENSEN, D.R., WHITELAW, A., THORESEN, M. The convulsive plasma level and pharmacokinetics of lignocaine in the newborn piglet. *Presentation published in Prenatal and Neonatal Medicine., 1996; 1 (Suppl. 1 ):124.*

17. BRISEID, K., HOEM, N.O., JOHANNESSEN S. A kallikrein fragment formed in human plasma in the absence of IgG shares immunological properties with factor XII. *Poster presentation, Gordon Conference on Kallikrein and Kinins, Barga, Italy May 1997.*
18. HOEM, N.O. Legemiddel, farmasi og helseinformasjon gjennom internett (Drug, pharmacy and health information by way of the Internet). *Invited presentation; Vastra kretsen , Local branch of <sup>rd</sup> Apotekarsocieteten, Goteburg, 1996.*
19. HOEM, N. O. Internettbaserte legemiddelinformasjonsressurser (Internet based drug info resources), *Invited presentation, <sup>th</sup> Lakemedelskongressen, Stockholm, 1997*
20. CARLSSON, K.C.; HOEM, N.O.; MOBERG, E.R.; MATHISEN, L.C. Analgesic effect of dextromethorphan in neuropathic pain. *LASP Nice, France. September 2000.*
21. HOEM, N.O. Klinisk farmakokinetikk. Virkelighet eller fata morgana? (Clinical Pharmacokinetics – Reality or a distant Mirage?) *Invited Presentation Population Interest Group Meeting Copenhagen. May 2000.*
22. HOEM, N.O, JELLIFFE, R. W.. Goal Oriented, Model Based Clinical Pharmacokinetics – *Invited Presentation Population Pharmacokinetics and Simulation Interest Group Meeting Copenhagen. May 2000.*
23. BOTNEN A, WANG X, JELLIFFE R, THOMAS M, and HOEM N: Population Pharmacokinetic Modeling via the World Wide Web. *Poster presentation Annual Meeting of the Population Analysis Group in Europe, Basel, Switzerland, June 7-8. 2001.*
24. HOEM N, and JELLIFFE R: An NPEM Populatin Analysis of Ciclosporine – Modelling Oral Drug Absorption as a Time-Dependent Function. *Poster presentation: Annual Meeting of the Population Analysis Group in Europe, Basel, Switzerland, June 7-8. 2001*
25. HOEM, N O. Modeling the oral absorption of drugs, an example with cyclosporine: *Invited oral presentation: Tenth Workshop 2001 on Adaptive Control of Drug Therapy: Individualizing Drug Therapy in 2001- Necessities, Difficulties, and Opportunities”, Hospital Geriatrique Antoine Charial, Francheville, France, 27-29 June, 2001.*



26. BOTNEN A, JELLIFFE R, THOMAS M, and HOEM N:  
Population Pharmacokinetic/Dynamic Modeling via the World Wide Web. Oral Presentation: *The 14 IEEE Symposium on Computer Based Medical Systems*, July 26-27, 2001, Bethesda MD. *Proceedings*, pp. 163-168.
27. HOEM, NO. Optimizing Transplant Chemotherapy. *First Italian Symposium on Population Pharmacokinetics*, March 19, 2002.
28. CARLSSON, KC, HANSEN, H, JELLIFFE, RW, HOEM, NO.  
Establishing a tool for individualized dosing of gabapentin - The use of a non-parametric population kinetics model in the MM-USCPACK software, a new tool for clinical dosage optimization.  
*Annual Meeting of the Population Analysis Group in Europe*, 12-13 June, Verona, Italy, 2003
29. CARLSSON, KC, HOEM, NO, GLAUSER, T, VINKS, AA.  
Can clinically useful population PK models for carbamazepine in pediatric epilepsy patients be developed based on routine therapeutic drug monitoring (TDM) data. *Annual Meeting of the Population Analysis Group in Europe*, 12-13 June, Uppsala, Sweden, 2004
30. HOEM, NO, BERINGER, P. A non-parametric (NPAG) population PK model of orally and intravenously administered linezolid. *Annual Meeting of the Population Analysis Group in Europe*, 12-13 June, Uppsala, Sweden, 2004.
31. HOEM, N., CARLSSON K.C. A population PK model of EPA and DHA after intake in phospholipid as well as in triglyceride form. Poster at *Annual Meeting of the Population Analysis Group in Europe*, 8-11 June, Berlin, Germany, 2010.
32. HOEM, N. Krill Phospholipids. Invited oral presentation at ILPS Lecithin Short Course, 10-11 June 2010, Ghent University, Belgium
- n# HOEM, N.  
A large number of invited lectures in the field of omega-3 fatty acids both regards manufacture, purification, characterization analytical chemistry, preclinical and clinical results: From 2008 until Present

## Reports

1. HOEM, N.  
Co-author: Overall Goals and detailed outline of objectives and practical implementation for a 3. Year specialization in Clinical Pharmacy in Norway. *Report to The Norwegian Association of Pharmacists.1991.*
2. HOEM, N.O. A survey and statistical Analysis in need in Postgraduate education among Norwegian Community Pharmacists and Pharmacy Owners. *Report to The Pharmacy Science Fund, Norwegian Association of Proprietor Pharmacists, Oslo 1992.*
3. HOEM, N.O, Overall plan, detailed description of objectives for subjects involved and methods of implementation for a one-year Post-graduate Continuing Education course for Norwegian Community Pharmacists. *Report to The Pharmacy Science Fund, Norwegian Association of Proprietor Pharmacists, Oslo 1993.*
4. HOEM, N.O. and JELLIFFE, R. W. Pharmacokinetic analysis of data from study PC T206/98 "A pharmacokinetic study of protoporphyrin IX formation in patients with actinic keratosis and basal cell carcinoma after topical application of P-1202 cream." *Report, Photocure ASA, Oslo. September1999.*
5. HOEM, N *et. al.:* Summary Report Eculizumab Pharmacokinetics and Pharmacodynamics. Compartmental Analysis and PK/PD Modeling; August 2006
6. HOEM, N *et. al.:* SHEPHERD C04-002 Study Compartmental Analysis and PK/PD Modeling; February 2007

Patents

A number of granted patents as well as patent applications